Evaluations of daily teriparatide using finite-element analysis over 12 months in rheumatoid arthritis patients.
Absorptiometry, Photon
Aged
Area Under Curve
Arthritis, Rheumatoid
/ blood
Biomarkers
/ blood
Bone Density
/ drug effects
Bone Density Conservation Agents
/ pharmacology
Bone Remodeling
/ drug effects
Drug Administration Schedule
Female
Finite Element Analysis
Humans
Logistic Models
Male
Teriparatide
/ pharmacology
Daily teriparatide
Finite-element analysis
N-terminal type I collagen propeptide
Osteoporosis
Rheumatoid arthritis
Journal
Journal of bone and mineral metabolism
ISSN: 1435-5604
Titre abrégé: J Bone Miner Metab
Pays: Japan
ID NLM: 9436705
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
30
05
2020
accepted:
17
08
2020
pubmed:
5
9
2020
medline:
10
4
2021
entrez:
5
9
2020
Statut:
ppublish
Résumé
The objective of this study was to quantitatively evaluate the effects of daily teriparatide on rheumatoid arthritis patients using predicted bone strength (PBS) assessed by quantitative computed tomography-based finite-element analysis (QCT/FEA) and using bone mineral density (BMD) assessed by dual-energy X-ray absorptiometry (DXA), and to prospectively investigate clinical determinants associated with PBS and BMD increases. Participants comprised 39 patients (mean age, 69 years; disease activity score assessing 28 joints with CRP, 3.0; previous vertebral fractures, 82%) enrolled in this study. BMD by DXA and PBS by QCT/FEA of lumbar spine (LS) and proximal femur were measured at baseline, and after 6 and 12 months. In the groups showing increases in these values, variables that may have affected these increases were evaluated using univariate logistic regression analysis. Daily teriparatide treatment significantly increased not only LS BMD, but also LS PBS in RA patients with osteoporosis after both 6 and 12 months of treatment. Increases in N-terminal type I procollagen propeptide (PINP) at 1 and 3 months were significantly associated with increased LS PBS at 12 months according to univariate logistic regression analysis. The threshold value for increased PINP at 1 month for increased PBS at 12 months was 75 µg/L. Increased LS PBS at 12 months was predicted by increased PINP at 1 month from baseline.
Identifiants
pubmed: 32886175
doi: 10.1007/s00774-020-01146-6
pii: 10.1007/s00774-020-01146-6
doi:
Substances chimiques
Biomarkers
0
Bone Density Conservation Agents
0
Teriparatide
10T9CSU89I
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
270-277Références
Hoes JN, Bultink EI, Lems WF (2015) Management of osteoporosis in rheumatoid arthritis patients. Expert Opin Pharmacother 16:559–571
doi: 10.1517/14656566.2015.997709
van Staa TP, Geusens P, Bijlsma JW, Leufkens HG, Cooper C (2006) Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum 54:3104–3112
doi: 10.1002/art.22117
Omata Y, Hagiwara F, Nishino J, Matsudaira K, Kadono Y et al (2014) Vertebral fractures affect functional status in postmenopausal rheumatoid arthritis patients. J Bone Miner Metab 32:725–731
doi: 10.1007/s00774-013-0552-8
Ochi K, Inoue E, Furuya T, Ikari K, Toyama Y et al (2015) Ten-year incidence of self-reported non-vertebral fractures in Japanese patients with rheumatoid arthritis: discrepancy between disease activity control and the incidence of non-vertebral fracture. Osteoporos Int 26:961–968
doi: 10.1007/s00198-014-2911-2
Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA et al (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. J Engl J Med 344:1434–1441
doi: 10.1056/NEJM200105103441904
Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R et al (2009) Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trail. Arthritis Rheum 60:3346–3355
doi: 10.1002/art.24879
Canalis E, Giustina A, Bilezikian JP (2007) Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 357:905–916
doi: 10.1056/NEJMra067395
Jiang Y, Zhao JJ, Mitlak BH, Wanq O, Genant HK et al (2003) Recombinant human parathyroid hormone (1–34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 18:1932–1941
doi: 10.1359/jbmr.2003.18.11.1932
Miyauchi A, Matsumoto T, Sugimoto T, Tsujimoto M, Warner MR et al (2010) Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label phases. Bone 47:493–502
doi: 10.1016/j.bone.2010.05.022
Soen S, Fujiwara S, Takayanagi R, Kajimoto K, Tsujimoto M et al (2017) Real-world effectiveness of daily teriparatide in Japanese patients with osteoporosis at high risk for fracture: final results from the 24-month Japan fracture Observational Study (JFOS). Curr Med Res Opin 33:2049–2056
doi: 10.1080/03007995.2017.1354826
Link TM, Kazakia G (2020) Update on imaging-based measurement of bone mineral density and quality. Curr Rheumatol Rep 22:13. https://doi.org/10.1007/s11926-020-00892-w
doi: 10.1007/s11926-020-00892-w
pubmed: 32270332
Solomon DH, Kremer J, Cutis JR, Hochberq MC, Reed G et al (2010) Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis 69:1920–1925
doi: 10.1136/ard.2009.122226
NIH consensus development panel on osteoporosis prevention (2001) Diagnosis and therapy. Osteoporosis prevention diagnosis and therapy. JAMA 285:785–796
doi: 10.1001/jama.285.6.785
Dall’Ara E, Pahr D, Varga P, Kainberger F, Zysset P (2012) QCT-based finite element models predict human vertebral strength in vitro significantly better than simulated DEXA. Osteoporos Int 23:563–572
doi: 10.1007/s00198-011-1568-3
Imai K, Ohnishi I, Bessho M, Nakamura K (2006) Nonlinear finite element model predicts vertebral bone strength and fracture site. Spine 31:1789–1794
doi: 10.1097/01.brs.0000225993.57349.df
Bessho M, Ohnishi I, Matsuyama J, Matsumoto T, Imai K et al (2007) Prediction of strength and strain of the proximal femur by a CT-based finite element method. J Biomech 40:1745–1753
doi: 10.1016/j.jbiomech.2006.08.003
Kaneko M, Ohnishi I, Matsumoto T, Ohashi S, Bessho M et al (2016) Prediction of proximal femur strength by a quantitative computed tomography-based finite element method- Creation of predicted strength data of the proximal femur according to age range in a normal population. Modern Rheumatol 26:151–155
doi: 10.3109/14397595.2015.1046220
Imai K, Ohnishi T, Matsumoto T, Yamamoto S, Nakamura K (2009) Assessment of vertebral fracture risk and therapeutic effects of alendronate in postmenopausal women using a quantitative computed tomography-based nonlinear finite element method. Osteoporos Int 20:801–810
doi: 10.1007/s00198-008-0750-8
Mawatari T, Miura H, Hamai S, Shuto T, Nakashima Y et al (2008) Vertebral strength changes in rheumatoid arthritis patients treated with alendronate, as assessed by finite element analysis of clinical computed tomography scans: a prospective randomized clinical trial. Arthritis Rheum 58:3340–3349
doi: 10.1002/art.23988
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324
doi: 10.1002/art.1780310302
Tsujimoto M, Chen P, Miyauchi A, Sowa H, Krege JH (2011) PINP as an aid for monitoring patients treated with teriparatide. Bone 48:798–803
doi: 10.1016/j.bone.2010.12.006
Gallagher JC, Rosen CJ, Chen P, Marcus R (2006) Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis. Bone 39:1268–1275
doi: 10.1016/j.bone.2006.06.007
Gluer CC (1999) Monitoring skeletal changes by radiological techniques. J Bone Miner Res 14:1952–1962
doi: 10.1359/jbmr.1999.14.11.1952
Hair JF, Anderson RE, Tatham RL, Black WC (1998) Multivariate data analysis with readings, 5th edn. Prentice-Hall, Englewood Cliffs
Hosmer DW, Lemeshow S (2000) Assessing the fit of the model. In: Hosmer DW, Lemshow S (eds) Applied logistic regression, 2nd edn. Wiley, New York, pp 143–202
doi: 10.1002/0471722146
Keaveny TM, McClung MR, Wan X, Kopperdahl DL, Mitlak BH et al (2012) Femoral strength in osteoporotic women treated with teriparatide or alendronate. Bone 50:165–170
doi: 10.1016/j.bone.2011.10.002
Obermayer-Pietsch BM, Marin F, McCloskey EV, Hadji P, Farrenrons J, Boonen S et al (2008) Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res 23:1591–1600
doi: 10.1359/jbmr.080506
Ebina K, Hashimoto J, Shi K, Kashii M, Hisao M et al (2014) Comparison of the effect of 18-month daily teriparatide administration on patients with rheumatoid arthritis and postmenopausal osteoporosis patients. Osteoporos Int 25:2755–5765
doi: 10.1007/s00198-014-2819-x
Ono K, Ohashi S, Oka H, Kadono Y, Yasui T et al (2016) The impact of joint disease on the Modified Health Assessment Questionnaire scores in rheumatoid arthritis patients: a cross-sectional study using the national database of rheumatic diseases by iR-net in Japan. Mod Rheumatol 26:529–533
doi: 10.3109/14397595.2015.1106640
Drake MT, Srinivasan B, Modder UI, Peterson JM, McCready LK et al (2010) Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab 95:5056–5062
doi: 10.1210/jc.2010-0720